Discovery of N-[(1-aryl-1H-indazol-5-yl)methyl]amides derivatives as smoothened antagonists for inhibition of the hedgehog pathway

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 15, 2009, Pages 4191-4195

  Dessole, Gabriella ^a   Branca, Danila ^a   Ferrigno, Federica ^a   Kinzel, Olaf ^a   Muraglia, Ester ^a   Palumbi, Maria Cecilia ^a   Rowley, Michael ^a   Serafini, Sergio ^a   Steinkühler, Christian ^a   Jones, Philip ^a  

^a IRBM   (Italy)

Author keywords

Hedgehog pathway; N (1 aryl 1H indazol 5 yl)methyl amide derivatives; Smoothened antagonists

Indexed keywords

AMIDE; INDAZOLE DERIVATIVE; N [1 (3 METHOXYPHENYL) 1H INDAZOL 5 YLMETHYL] 2 PROPYLPENTANAMIDE; PROTEIN INHIBITOR; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

AMIDES; CATALYSIS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INDAZOLES; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

ERINACEIDAE;

EID: 67649977914     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.05.112     Document Type: Article

References (21)

1. Jiang J., and Hui C. Dev. Cell 15 (2008) 801
2. Rubin L.L., and de Sauvage F.J. Nat. Rev. Drug Disc. 5 (2006) 1026
3. Di Magliano M.P., and Hebrok M. Nat. Rev. Cancer 3 (2003) 903
4. Chiang C., Litingtung Y., Lee E., Young K.E., Corden J.L., Westphal H., and Beachy P.A. Nature 383 (1996) 407
5. Roessler E., Belloni E., Gaudenz K., Jay P., Berta P., Scherer S.W., Tsui L.C., and Muenke M. Nat. Genet. 14 (1996) 357
6. Belloni E., Muenke M., Roessler E., Traverso G., Siegel-Bartelt J., Frumkin A., Mitchell H.F., Donis-Keller H., and Helms C. Nat. Genet. 14 (1996) 353
7. Evangelista M., Tian H., and de Sauvage F.J. Clin. Cancer Res. 12 (2006) 5924
8. Chen J.K., Taipale J., Cooper M.K., and Beachy P.A. Genes Dev. 16 (2002) 2743
9. Berman D.M., Karhadkar S.S., Hallahan A.R., Pritchard J.I., Eberhart C.G., Watkins D.N., Chen J.K., Cooper M.K., Taipale J., Olson J.M., and Beachy P.A. Science 297 (2002) 1159
10. Mahindroo N., Chandanamali P., and Fujii N. J. Med. Chem. (2009) 10.1021/jm801420y
11. Gallinari P., Filocamo G., Jones P., Pazzaglia S., and Steinkühler C. Expert Opin. Drug Disc. 4 (2009) 525
12. LoRusso, P. M.; Rudin, C. M.; Borad, M. J.; Vernillet, L.; Darbonne, W. C.; Mackey, H.; DiMartino, J. F.; de Sauvage, F.; Low, J. A.; Von Hoff, D. D. J. Clin. Oncol. (Meeting Abstracts) 2008, 26, 3516.
13. 50 value was determined based on the residual Gli-dependent transcriptional activity, and cell viability.
14. 50 value was determined based on the residual fluorescence normalised for PI values.
15. Pazzaglia S., Tanori M., Mancuso M., Rebessi S., Leonardi S., Di Majo V., Covelli V., Atkinson M.J., Hahn H., and Saran A. Oncogene 25 (2006) 1165
16. Pazzaglia S., Tanori M., Mancuso M., Gessi M., Pasquali E., Oliva M.A., Rebessi S., Di Majo V., Covelli V., Giangaspero F., and Saran A. Oncogene 25 (2006) 5575
17. Sanderson, P.; Lyle, T.; Dorsey, B.; Santon, M.; Nylor-Olsen, A. M. WO 00/26210.
18. +.
19. Antilla J.C., Baskin J.M., Barder T.E., and Buchwald S.L. J. Org. Chem. 69 (2004) 5578
20. +.All the compounds prepared as described for 26 were obtained in comparable yields (>50%).
21. Compounds synthesized acconding to route A were obtained in 25-50% yields from 37. Compound 25 was obtained in 35% yields.